Hepion Pharmaceuticals Q3 loss widens to $4.58M
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Hepion Pharmaceuticals, Inc. (HEPA) reported no revenue for the three and nine months ended September 30, 2026. Third-quarter net loss was $4,582,920, versus $472,506 a year earlier, largely reflecting a noncash loss from warrant fair-value changes. Nine-month net loss narrowed to $6,641,948 from $7,620,965; operating cash use was $1,697,270. Cash was $4,255,346 at September 30.
Management cited substantial doubt about the company’s ability to continue as a going concern without additional capital. It also reported three material weaknesses that made disclosure controls and procedures ineffective; remediation was underway, but the weaknesses were not yet considered remediated.
After quarter-end, Hepion increased authorized common shares from 120,000,000 to 750,000,000 and acquired Gravitas Life Sciences, LLC for $2,000,000 cash and the right to receive 25,000,000 common shares, subject to a 19.99% post-issuance cap; it also paid $135,000. For GLS’s gambling-disorder program, the FDA said the proposed Phase 2 design and endpoint were, in general, appropriate. GLS intends to file an IND in 2027; the final Phase 2 design may change following review.
How this balance works
Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.
It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.
Rhea-AI Sentiment measures something else, the tone of the wording.
Positive
- Moderate pointNine-month net loss fell to $6,641,948 from $7,620,965.
Negative
- Major pointSubstantial doubt remains about going-concern status without additional capital.
- Major pointThree material weaknesses left disclosure controls ineffective as of September 30, 2026.
- Moderate pointThird-quarter net loss reached $4,582,920, largely reflecting noncash warrant revaluation.
Filing Explained
As of September thirtieth, one hundred six million four hundred twenty-nine thousand seven hundred ninety-nine potential shares were listed, not issued.
This unaudited Form 10-Q reports that Hepion closed its July private placement, issuing 61,100,000 common shares and warrants for 61,100,000 shares; its August and September offerings closed with 10,200,000 common shares and warrants for 10,200,000 shares.
Those warrants are exercisable at
On
Key Figures
Key Terms
substantial doubt financial
material weaknesses in our internal control over financial reporting regulatory
derivative financial instruments—warrants financial
505(b)(2) New Drug Application regulatory
buccal mucosa medical
absolute bioavailability medical
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What were HEPA’s results for the third quarter of 2026?
What were the terms of HEPA’s acquisition of GLS?
What did the FDA say about GLS’s gambling-disorder program?
AI-generated analysis. How Rhea-AI works. Not financial advice.
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM
For
the Quarterly Period Ended
Or
For the transition period from to
Commission
File Number

(Exact name of registrant as specified in its charter)
| (State or other jurisdiction of | (I.R.S. Employer | |
| incorporation or organization) | Identification Number) |
(Address of Principal Executive Offices)
Registrant’s telephone number, including area code
34 Shrewsbury Ave., Suite 1D
Red Bank, NJ 07701
(Former name or former address, if changed since last report)
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class | Trading Symbol(s) | Name of each exchange on which registered | ||
| OTC QB |
Indicate
by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange
Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2)
has been subject to such filing requirements for the past 90 days.
Indicate
by check mark whether the Registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule
405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the Registrant
was required to submit such files).
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act.:
| Large accelerated filer ☐ | Accelerated filer ☐ | Smaller
reporting company |
Emerging
growth company |
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Indicate
by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No
The number of shares of the registrant’s Common Stock outstanding
as of November 8, 2026 was
HEPION PHARMACEUTICALS, INC.
FORM 10-Q
TABLE OF CONTENTS
| Page | ||
| PART I—FINANCIAL INFORMATION | ||
| Item 1. | Condensed Consolidated Financial Statements (unaudited): | 2 |
| Condensed Consolidated Balance Sheets | 2 | |
| Condensed Consolidated Statements of Operations | 3 | |
| Condensed Consolidated Statements of Comprehensive Loss | 4 | |
| Condensed Consolidated Statements of Changes in Stockholders’ Equity | 5 | |
| Condensed Consolidated Statements of Cash Flows | 6 | |
| Notes to Condensed Consolidated Financial Statements | 7 | |
| Item 2. | Management’s Discussion and Analysis of Financial Condition and Results of Operations | 17 |
| Item 3. | Quantitative and Qualitative Disclosures About Market Risk | 23 |
| Item 4. | Controls and Procedures | 23 |
| PART II—OTHER INFORMATION | ||
| Item 1A. | Risk Factors | 24 |
| Item 6. | Exhibits | 24 |
| SIGNATURES | 25 | |
CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS
This Quarterly Report on Form 10-Q for Hepion Pharmaceuticals, Inc. may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Such forward-looking statements are characterized by future or conditional verbs such as “may,” “will,” “expect,” “intend,” “anticipate,” believe,” “estimate” and “continue” or similar words. You should read statements that contain these words carefully because they discuss future expectations and plans, which contain projections of future results of operations or financial condition or state other forward-looking information. Such statements are only predictions and our actual results may differ materially from those anticipated in these forward-looking statements. We believe that it is important to communicate future expectations to investors. However, there may be events in the future that we are not able to accurately predict or control. Factors that may cause such differences include, but are not limited to, those discussed under Item 1A. Risk Factors and elsewhere in the audited consolidated financial statements as of and for the year ended December 31, 2025 contained in our Annual Report on Form 10-K filed with the Securities and Exchange Commission on March 12, 2026, as well as under Item 1A . Risk Factors within this Form 10-Q. These factors include the uncertainties associated with:
| ● | our ability to raise substantial additional capital to continue as a going concern and fund our planned operations in the near term; |
| ● | estimates regarding our expenses, use of cash, timing of future cash needs and anticipated capital requirements; |
| ● | success in retaining, or changes required in, our officers, key employees or directors; |
| ● | our public securities’ potential liquidity and trading; |
| ● | our ability to obtain and maintain regulatory approval of our product candidates, and any related restrictions, limitations or warnings in the label of any of our product candidates, if approved; |
| ● | our plans to pursue research and development of other future product candidates; |
| ● | the potential advantages of our product candidates and those being developed; |
| ● | the rate and degree of market acceptance and clinical utility of our product candidates; |
| ● | the success of our collaborations and partnerships with third parties; |
| ● | our estimates regarding the potential market opportunity for our product candidates; |
| ● | our sales, marketing and distribution capabilities and strategy; |
| ● | our ability to establish and maintain arrangements for manufacture of our product candidates; |
| ● | our ability to compete with companies currently marketing or engaged in the development of treatments for indications that our product candidates are designed to target; and |
| ● | our intellectual property position, including the strength and enforceability of our intellectual property rights. |
We do not assume any obligation to update forward-looking statements as circumstances change and thus you should not unduly rely on these statements.
| 1 |
| Table of Contents |
PART I—FINANCIAL INFORMATION
Item 1. Condensed Consolidated Financial Statements
HEPION PHARMACEUTICALS, INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED BALANCE SHEETS
(Unaudited)
| September 30, 2026 | December 31, 2025 | |||||||
| Assets | ||||||||
| Current assets: | ||||||||
| Cash | $ | $ | ||||||
| Prepaid expenses | ||||||||
| Related party receivable | — | |||||||
| Total current assets | ||||||||
| Right-of-use asset | — | |||||||
| Other assets | — | |||||||
| Total assets | $ | $ | ||||||
| Liabilities and Stockholders’ Equity | ||||||||
| Current liabilities: | ||||||||
| Accounts payable | $ | $ | ||||||
| Accrued expenses | ||||||||
Accrued interest | — | |||||||
| Related party note payable, current | ||||||||
Operating lease liability, current | — | |||||||
| Total current liabilities | ||||||||
Operating lease liability, non-current | — | |||||||
| Derivative financial instruments—warrants | ||||||||
| Total liabilities | ||||||||
| Commitments and contingencies (see Note 10) | - | - | ||||||
| Stockholders’ equity: | ||||||||
| Series A convertible preferred stock, stated value $ | ||||||||
| Series C convertible preferred stock, stated value $ | ||||||||
| Convertible preferred stock | ||||||||
| Common stock—$ | ||||||||
| Treasury stock, at cost; | ( | ) | — | |||||
| Additional paid-in capital | ||||||||
| Accumulated other comprehensive income. | ||||||||
| Accumulated deficit | ( | ) | ( | ) | ||||
| Total stockholders’ equity (deficit) | ( | ) | ||||||
| Total liabilities and stockholders’ equity | $ | $ | ||||||
The accompanying notes are an integral part of these condensed consolidated financial statements (unaudited).
| 2 |
| Table of Contents |
HEPION PHARMACEUTICALS, INC. AND SUBSIDIARIES
Condensed Consolidated Statements of Operations
(Unaudited)
| 2026 | 2025 | 2026 | 2025 | |||||||||||||
| Three Months Ended September 30, | Nine Months Ended September 30, | |||||||||||||||
| 2026 | 2025 | 2026 | 2025 | |||||||||||||
| Revenues | $ | — | $ | — | $ | — | $ | — | ||||||||
| Cost and expenses: | ||||||||||||||||
| Research and development | — | |||||||||||||||
| General and administrative | ||||||||||||||||
| Asset impairment loss | — | — | — | |||||||||||||
| Total operating expenses | ||||||||||||||||
| Loss from operations | ( | ) | ( | ) | ( | ) | ( | ) | ||||||||
| Other income (expense): | ||||||||||||||||
| Interest income (expense) | ( | ) | ( | ) | ||||||||||||
| Other income (expense), net | — | — | ||||||||||||||
| Change in fair value of derivative financial instruments-warrants | ( | ) | ( | ) | ( | ) | ||||||||||
| Net loss | $ | ( | ) | $ | ( | ) | $ | ( | ) | $ | ( | ) | ||||
| Weighted-average common shares outstanding: | ||||||||||||||||
| Basic and diluted | ||||||||||||||||
| Net loss per common share: (see Note 9) | ||||||||||||||||
| Basic and diluted | $ | ( | ) | $ | ( | ) | $ | ( | ) | $ | ( | ) | ||||
The accompanying notes are an integral part of these condensed consolidated financial statements (unaudited).
| 3 |
| Table of Contents |
HEPION PHARMACEUTICALS, INC. AND SUBSIDIARIES
Condensed Consolidated Statements of Comprehensive Loss
(Unaudited)
| 2026 | 2025 | 2026 | 2025 | |||||||||||||
Three Months Ended September 30, | Nine Months Ended September 30, | |||||||||||||||
| 2026 | 2025 | 2026 | 2025 | |||||||||||||
| Net loss | $ | ( | ) | $ | ( | ) | $ | ( | ) | $ | ( | ) | ||||
| Other comprehensive income (loss): | ||||||||||||||||
| Foreign currency translation | — | — | — | — | ||||||||||||
| Total other comprehensive income (loss) | — | — | — | — | ||||||||||||
| Comprehensive loss | $ | ( | ) | $ | ( | ) | $ | ( | ) | $ | ( | ) | ||||
The accompanying notes are an integral part of these condensed consolidated financial statements (unaudited).
| 4 |
| Table of Contents |
HEPION PHARMACEUTICALS, INC. AND SUBSIDIARIES
Condensed Consolidated Statements of Changes in Stockholders’ Equity
(Unaudited)
| Shares | Amount | Shares | Amount | Shares | Amount | stock | Capital | Income | Deficit | Equity | ||||||||||||||||||||||||||||||||||
| Preferred Stock | Preferred Stock | Additional | Accumulated other | Total | ||||||||||||||||||||||||||||||||||||||||
| Series A | Series C | Common Stock | Treasury | Paid in | Comprehensive | Accumulated | Stockholders’ | |||||||||||||||||||||||||||||||||||||
| Shares | Amount | Shares | Amount | Shares | Amount | stock | Capital | Income | Deficit | Equity | ||||||||||||||||||||||||||||||||||
| Balance at December 31, 2025 | $ | $ | $ | — | $ | $ | $ | ( | ) | $ | ||||||||||||||||||||||||||||||||||
| Net loss | — | — | — | — | — | — | - | — | — | ( | ) | ( | ) | |||||||||||||||||||||||||||||||
| Balance at March 31, 2026 | $ | $ | - | $ | $ | $ | ( | ) | $ | |||||||||||||||||||||||||||||||||||
| Net loss | — | — | — | — | — | — | - | — | — | ( | ) | ( | ) | |||||||||||||||||||||||||||||||
| Issuance of common stock, net | — | — | — | — | - | — | — | |||||||||||||||||||||||||||||||||||||
| Balance at June 30, 2026 | $ | $ | - | $ | $ | $ | ( | ) | $ | |||||||||||||||||||||||||||||||||||
| Net loss | — | — | — | — | — | — | — | — | — | ( | ) | ( | ) | |||||||||||||||||||||||||||||||
| Stock-based compensation expense | — | — | — | — | — | — | - | — | — | |||||||||||||||||||||||||||||||||||
| Issuance of common stock and warrants, net of warrant liabilities | — | — | — | — | - | — | — | |||||||||||||||||||||||||||||||||||||
| Reclassification of July and August 2026 Offering warrants to liabilities | — | — | — | — | — | — | — | ( | ) | — | — | ( | ) | |||||||||||||||||||||||||||||||
Warrants issued in connection with convertible note | — | — | — | — | — | — | — | — | — | |||||||||||||||||||||||||||||||||||
| Common stock returned and held in treasury ( | — | — | — | — | — | — | ( | ) | — | — | — | ( | ) | |||||||||||||||||||||||||||||||
| Balance at September 30, 2026 | $ | $ | ( | ) | $ | $ | $ | ( | ) | $ | ( | ) | ||||||||||||||||||||||||||||||||
| Shares | Amount | Shares | Amount | Shares | Amount | Capital | Income | Deficit | Equity | |||||||||||||||||||||||||||||||
| Preferred Stock | Preferred Stock | Additional | Accumulated other | Total | ||||||||||||||||||||||||||||||||||||
| Series A | Series C | Common Stock | Paid in | Comprehensive | Accumulated | Stockholders’ | ||||||||||||||||||||||||||||||||||
| Shares | Amount | Shares | Amount | Shares | Amount | Capital | Income | Deficit | Equity | |||||||||||||||||||||||||||||||
| Balance at December 31, 2024 | $ | $ | $ | $ | $ | $ | ( | ) | $ | ( | ) | |||||||||||||||||||||||||||||
| Net loss | — | — | — | — | — | — | — | — | ( | ) | ( | ) | ||||||||||||||||||||||||||||
| Stock-based compensation expense | — | — | — | — | — | — | — | — | ||||||||||||||||||||||||||||||||
| Issuance of restricted stock units | — | — | — | — | — | — | — | — | — | |||||||||||||||||||||||||||||||
| Issuance of common stock and pre-funded warrants, net | — | — | — | — | — | — | ||||||||||||||||||||||||||||||||||
| Issuance of common stock in connection with stock split | — | — | — | — | ( | ) | — | — | — | |||||||||||||||||||||||||||||||
| Conversion of 2025 Series B warrants into common stock | — | — | — | — | — | — | ||||||||||||||||||||||||||||||||||
| Balance at March 31, 2025 | $ | $ | $ | $ | $ | ( | ) | $ | ||||||||||||||||||||||||||||||||
| Net loss | — | — | — | — | — | — | — | — | ( | ) | ( | ) | ||||||||||||||||||||||||||||
| Conversion of 2025 Series B warrants into common stock | — | — | — | — | — | — | ||||||||||||||||||||||||||||||||||
| Issuance of common stock in connection with license agreement | — | — | — | — | — | — | ||||||||||||||||||||||||||||||||||
| Balance at June 30, 2025 | $ | $ | $ | $ | $ | ( | ) | $ | ||||||||||||||||||||||||||||||||
| Balance | $ | $ | $ | $ | $ | ( | ) | $ | ||||||||||||||||||||||||||||||||
| Net loss | — | — | — | — | — | — | — | — | ( | ) | ( | ) | ||||||||||||||||||||||||||||
| Balance at September 30, 2025 | $ | $ | $ | $ | $ | ( | ) | $ | ||||||||||||||||||||||||||||||||
| Balance | $ | $ | $ | $ | $ | ( | ) | $ | ||||||||||||||||||||||||||||||||
The accompanying notes are an integral part of these condensed consolidated financial statements (unaudited).
| 5 |
| Table of Contents |
HEPION PHARMACEUTICALS, INC. AND SUBSIDIARIES
Condensed Consolidated Statements of Cash Flows
(Unaudited)
| 2026 | 2025 | |||||||
| Nine Months Ended September 30, | ||||||||
| 2026 | 2025 | |||||||
| Cash flows from operating activities: | ||||||||
| Net loss | $ | ( | ) | $ | ( | ) | ||
| Adjustments to reconcile net loss to net cash used in operating activities: | ||||||||
| Stock-based compensation | ||||||||
| Asset impairment loss | — | |||||||
| Change in fair value of derivative financial instruments—warrants | ||||||||
| Offering costs allocated to warrant liabilities | — | |||||||
| Gain on return of common stock | ( | ) | — | |||||
| Amortization of debt discount and issuance costs | — | |||||||
| Changes in operating assets and liabilities: | ||||||||
| Accounts payable and accrued expenses | ( | ) | ||||||
| Prepaid expenses and other assets | ||||||||
| Net cash used in operating activities | ( | ) | ( | ) | ||||
| Cash flows from investing activities: | ||||||||
| Investment in license agreement | — | ( | ) | |||||
| Related party loan receivable | ( | ) | — | |||||
| Net cash used in investing activities | ( | ) | ( | ) | ||||
| Cash flows from financing activities: | ||||||||
| Proceeds from the issuance of common stock and warrants, net | ||||||||
| Equity issuance costs | ( | ) | ( | ) | ||||
| Proceeds from note payable, net | — | |||||||
| Payments on notes payable | ( | ) | ( | ) | ||||
| Net cash provided by financing activities | ||||||||
| Net increase (decrease) in cash | ||||||||
| Cash at beginning of period | ||||||||
| Cash at end of period | $ | $ | ||||||
| Supplementary disclosure of non-cash financing activities: | ||||||||
| Issuance of Note Payable for payment of prepaid expense | — | |||||||
| Cashless Exercise of 2025 Series B Warrants | $ | — | $ | |||||
| Issuance of common stock in connection with license agreement | $ | — | $ | |||||
| Common stock returned and held in treasury | — | |||||||
Warrants issued in connection with convertible note | — | |||||||
Right-of-use asset obtained in exchange for operating lease liability | — | |||||||
| Initial fair value of warrants liabilities issued in private placements | — | |||||||
| Reclassification of warrants from equity to liabilities | — | |||||||
The accompanying notes are an integral part of these condensed consolidated financial statements (unaudited).
| 6 |
| Table of Contents |
HEPION PHARMACEUTICALS, INC. AND SUBSIDIARIES
Notes to Condensed Consolidated Financial Statements
(Unaudited)
1. Business Overview
Hepion Pharmaceuticals, Inc. (we, our, or us) is a medical diagnostic company headquartered in Red Bank, New Jersey, that was previously focused on the development of drug therapy for treatment of chronic liver diseases. Our cyclophilin inhibitor, rencofilstat (formerly CRV431), was being developed to offer benefits to address multiple complex pathologies related to the progression of liver disease.
On
February 25, 2026, we entered into an intellectual property license agreement with Cirna Diagnostics, LLC (“Cirna”)
pursuant to which we licensed certain liver disease diagnostic assets from Cirna. We paid an upfront payment of $
2. Basis of Presentation
Basis of Presentation
These unaudited condensed consolidated financial statements have been prepared following the requirements of the Securities and Exchange Commission (“SEC”) and accounting principles generally accepted in the United States of America (“U.S. GAAP”) for interim reporting. In the opinion of management, the accompanying unaudited condensed consolidated financial statements include all adjustments, which include only normal recurring adjustments, necessary to present fairly our interim financial information. The consolidated balance sheet as of December 31, 2025, was derived from the audited annual consolidated financial statements but does not include all disclosures required by U.S. GAAP. The accompanying unaudited condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and notes thereto as of and for the year ended December 31, 2025, contained in our Annual Report on Form 10-K filed with the SEC on March 12, 2026.
Principles of Consolidation
The accompanying condensed consolidated financial statements include our accounts and the accounts of our subsidiaries, Contravir Research Inc. and Hepion Research Corp, which conduct their operations in Canada (all subsidiaries are currently dormant). All intercompany balances and transactions have been eliminated in consolidation.
Going Concern
As
of September 30, 2026, we had $
| 7 |
| Table of Contents |
HEPION PHARMACEUTICALS, INC. AND SUBSIDIARIES
Notes to Condensed Consolidated Financial Statements
(Unaudited)
These condensed consolidated financial statements have been prepared under the assumption that we will continue as a going concern. Due to our recurring and expected continuing losses from operations, we have concluded there is substantial doubt in our ability to continue as a going concern within one year of the issuance of these condensed consolidated financial statements without additional capital becoming available to us. The condensed consolidated financial statements do not include any adjustments that might result from the outcome of this uncertainty.
We cannot be certain that additional funding will be available on acceptable terms, or at all. To the extent that we raise additional funds by issuing equity securities, our stockholders may experience significant dilution. Any debt financing, if available, may involve restrictive covenants that impact our ability to conduct business. If we are unable to raise additional capital when required or on acceptable terms, we may have to (i) seek collaborators for our product candidates on terms that are less favorable than might otherwise be available; or (ii) relinquish or otherwise dispose of rights to technologies, product candidates or products that we would otherwise seek to develop or commercialize on unfavorable terms.
On
April 21, 2026, we entered into securities purchase agreements (the “Agreements”) with certain accredited investors (the
“Investors”) pursuant to which the Company agreed to sell and issue to the Investors in a private placement offering (the
“April 2026 Offering”), an aggregate of
On
July 31, 2026, we entered into securities purchase agreements with certain accredited investors pursuant to which the Company agreed
to sell and issue
In
addition, on August 26, 2026 (the “August 2026 Offering”) and September 29, 2026 (the “September 2026 Offering”),
we entered into securities purchase agreements with certain accredited investors pursuant to which the Company agreed to sell and issue
3. Summary of Significant Accounting Policies
Use of Estimates
The preparation of condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements and the reported amounts of expenses during the reporting period. Changes in estimates and assumptions are reflected in reported results in the period in which they become known. Actual results could differ from those estimates.
Our significant accounting policies are disclosed in the audited consolidated financial statements for the year ended December 31, 2025, included in our Annual Report on Form 10-K. Since the date of such consolidated financial statements, there have been no changes to our significant accounting policies.
Recent Accounting Pronouncements
There are no recent accounting pronouncements that will have a material effect on our condensed consolidated financial statements for the three and nine months ended September 30, 2026.
| 8 |
| Table of Contents |
HEPION PHARMACEUTICALS, INC. AND SUBSIDIARIES
Notes to Condensed Consolidated Financial Statements
(Unaudited)
4. Stockholders’ Equity
On
April 21, 2026, the Company entered into securities purchase agreements (the “Agreements”) with certain accredited investors
(the “Investors”) pursuant to which the Company agreed to sell and issue to the Investors in a private placement offering
(the “Offering”), an aggregate of
On
July 22, 2026, the Company and New Day Diagnostics LLC (“New Day”) entered into a termination and release agreement (the
“Termination Agreement”) terminating the Intellectual Property License Agreement dated May 9, 2025, Amendment I to the Intellectual
Property License Agreement dated October 16, 2025, and the Commercial Consulting Services Statement of Work dated June 23, 2025. Pursuant
to the Termination Agreement, New Day returned
On
July 31, 2026, we closed the July 2026 Offering, pursuant to which the Company agreed to sell and issue
In
addition, during third quarter of 2026, we closed the August 2026 Offering and the September 2026 Offering, pursuant to which the Company
agreed to sell an aggregate of
Because the Company did not have sufficient authorized and unissued shares of common stock to settle all of the warrants
issued in the July 2026, August 2026 and September 2026 Offerings and the shares issuable on conversion of the Convertible Note (see Note
5) until its authorized common stock was increased on October 1, 2026, the Company applied its sequencing policy, under which instruments
are reclassified to liabilities beginning with the earliest-issued instrument. Under this policy,
Series A Convertible Preferred Stock
Each
share of the Series A is convertible at the option of the holder into the number of shares of common stock determined by dividing the
stated value of such share by the conversion price that is subject to adjustment. As of September 30, 2026, there were
Series C Convertible Preferred Stock Issuance
As
of September 30, 2026, there were
Common Stock and Warrant Offering
The fair value of these liability classified warrants was estimated using the Black-Scholes option pricing model. This method of valuation involves using inputs such as the fair value of our common stock, historical volatility, the contractual term of the warrants, risk-free interest rates and dividend yields. Due to the nature of these inputs, the valuation of the warrants is considered a Level 2 measurement (see Note 6). The following assumptions were used to measure the Series A and Series B-1 Warrants as of September 30, 2026 and December 31, 2025.
Schedule of Assumptions Used to Calculate Fair Value of Liability
| September 30, 2026 | December 31, 2025 | |||||||
| Stock price | $ | $ | ||||||
| Expected warrant term (years) | ||||||||
| Risk-free interest rate | % | % | ||||||
| Expected volatility | % | % | ||||||
| Dividend yield | — | — | ||||||
| 9 |
| Table of Contents |
HEPION PHARMACEUTICALS, INC. AND SUBSIDIARIES
Notes to Condensed Consolidated Financial Statements
(Unaudited)
The exercise price, amount of warrants outstanding and fair value for all warrants as of September 30, 2026 and December 31, 2025 are as follows:
Schedule of Warrants Outstanding and Fair Value for Warrants
| September 30, 2026 | December 31, 2025 | |||||||||||||||||||||||
| Exercise Price | Warrants Outstanding | Fair Value | Exercise Price | Warrants Outstanding | Fair Value | |||||||||||||||||||
| Series A Warrants | $ | — | $ | — | ||||||||||||||||||||
| Series B-1 Warrants | $ | — | $ | — | ||||||||||||||||||||
| 2025 Series A Warrants | $ | $ | $ | $ | ||||||||||||||||||||
| July 2026 Offering Warrants | $ | $ | — | — | — | |||||||||||||||||||
| August 2026 Offering Warrants (liability-classified portion) | $ | $ | — | — | — | |||||||||||||||||||
| Total | $ | $ | ||||||||||||||||||||||
On
January 23, 2025, we consummated a “best efforts” public offering of
The
Company accounted for
As
part of the transaction, the Company incurred equity issuance costs of $
The
combined offering price of each share of common stock together with the accompanying Series A and Series B common warrants is $
The
Series B warrants contained certain volume weighted average price provisions that reset the exercise price to a minimum floor price of
$
As
of April 4, 2025 all of the Series B warrants were exercised into common shares at a weighted average reset price of $
| 10 |
| Table of Contents |
HEPION PHARMACEUTICALS, INC. AND SUBSIDIARIES
Notes to Condensed Consolidated Financial Statements
(Unaudited)
The fair value of the liability classified warrants was estimated using the Black-Scholes option pricing model. This method of valuation involves using inputs such as the fair value of our common stock, historical volatility, the contractual term of the warrants, risk-free interest rates and dividend yields. Due to the nature of these inputs, the valuation of the warrants is considered a Level 2 measurement (see Note 6).
2026 Private Placement Warrants
Of
the warrants to purchase
The following assumptions were used to measure warrant liabilities at period end.
| September 30, | December 31, | |||||||
| 2026 | 2025 | |||||||
| Stock price | $ | $ | ||||||
| Expected warrant term (years) | ||||||||
| Risk-free interest rate | % | % | ||||||
| Expected volatility | % | % | ||||||
| Dividend yield | — | — | ||||||
The
warrant to purchase
The following table sets forth the components of changes in our derivative financial instruments liability balance for the nine months ended September 30, 2026.
Schedule of Derivative Liabilities at Fair Value
| Date | Number of Warrants Outstanding | Derivative Liability | ||||||
| Balance of derivative liability at December 31, 2025 | $ | |||||||
| Issuance of warrants classified as liabilities | ||||||||
| Change in fair value of warrants | — | |||||||
| Balance of derivative liability at September 30, 2026 | ||||||||
5. Notes Payable
On
March 15, 2025, the Company entered into a one-year Directors and Officers Liability Insurance agreement for $
On
September 3, 2026, the Company entered into a convertible note purchase agreement (the “Convertible Note”) with Gravitas
Capital LP pursuant to which the Company issued a $
The
Company evaluated the Convertible Note and Gravitas Warrant under ASC 480, Distinguishing Liabilities from Equity, ASC 815,
Derivatives and Hedging, and ASC 470-20, Debt with Conversion and Other Options. The Gravitas Warrant is a freestanding financial
instrument that is equity-classified. The proceeds of $
| 11 |
| Table of Contents |
HEPION PHARMACEUTICALS, INC. AND SUBSIDIARIES
Notes to Condensed Consolidated Financial Statements
(Unaudited)
6. Fair Value Measurements
The following table presents our liabilities that are measured and recognized at fair value on a recurring basis classified under the appropriate level of the fair value hierarchy at September 30, 2026 and December 31, 2025.
Schedule of Liabilities Measured and Recognized at Fair Value on a Recurring Basis
| Description | Fair value | (Level 1) | (Level 2) | (Level 3) | ||||||||||||
| Fair Value Measurement at Reporting Date Using | ||||||||||||||||
| Description | Fair value | (Level 1) | (Level 2) | (Level 3) | ||||||||||||
| As of September 30, 2026: | ||||||||||||||||
| Derivative liabilities related to warrants | $ | $ | — | $ | $ | — | ||||||||||
| As of December 31, 2025: | ||||||||||||||||
| Derivative liabilities related to warrants | $ | $ | — | $ | $ | — | ||||||||||
The unrealized gains or losses on the derivative liabilities are recorded as a change in fair value of derivative financial instruments—warrants in our consolidated statement of operations. See Note 4 for a rollforward of the derivative liability for the nine months ended September 30, 2026.
7. Accrued Liabilities
The following table presents our accrued liabilities at September 30, 2026 and December 31, 2025.
Schedule of Accrued Liabilities
| September 30, 2026 | December 31, 2025 | |||||||
| Payroll related | $ | $ | ||||||
| Accrued taxes | — | |||||||
| Other | ||||||||
| Total accrued expenses | $ | $ | ||||||
8. Accounting for Share-Based Payments
On
June 3, 2013, we adopted the 2013 Equity Incentive Plan (the 2013 Plan), which expired in June 2023 and we are no longer making grants
under it. Stock options granted under the 2013 Plan typically vested after
In
April 2023, our board of directors approved the 2023 Omnibus Equity Incentive Plan (the 2023 Plan), which became effective in June 2023
upon stockholder approval. The 2023 Plan allowed for the grant of up to
| 12 |
| Table of Contents |
HEPION PHARMACEUTICALS, INC. AND SUBSIDIARIES
Notes to Condensed Consolidated Financial Statements
(Unaudited)
We classify stock-based compensation expense in our consolidated statement of operations in the same way the award recipient’s payroll costs are classified or in which the award recipients’ service payments are classified. We recorded stock-based compensation expense as follows:
Schedule of Stock Based Compensation Expense
| 2026 | 2025 | 2026 | 2025 | |||||||||||||
Three Months Ended September 30, | Nine Months Ended September 30, | |||||||||||||||
| 2026 | 2025 | 2026 | 2025 | |||||||||||||
| General and administrative | $ | $ | — | $ | $ | |||||||||||
| Research and development | — | — | ||||||||||||||
| Total stock-based compensation expense | $ | $ | — | $ | $ | |||||||||||
A summary of stock option activity under the 2013 Plan and 2023 Plan is presented as follows:
Schedule of Stock Option Activity
| Number of Options | Weighted Average Exercise Price Per Share | Intrinsic Value | Weighted Average Remaining Contractual Term | |||||||||||
| Balance outstanding, December 31, 2025 | $ | $ | — | |||||||||||
| Granted | ||||||||||||||
| Forfeited | ( | ) | $ | $ | — | |||||||||
| Balance outstanding, September 30, 2026 | $ | $ | — | |||||||||||
| Awards outstanding, vested awards and those expected to vest at September 30, 2026 | $ | $ | — | |||||||||||
| Vested and exercisable at September 30, 2026 | $ | $ | — | |||||||||||
The
weighted-average grant date fair value of stock options granted during the three and nine months ended September 30, 2026 was $
9. Loss per Share
Basic and diluted net loss per common share was determined by dividing net loss attributable to common stockholders by the weighted-average common shares outstanding during the period.
Schedule of Computation of Basic and Diluted Net Loss Per Share
| Basic and diluted net loss per common share: | 2026 | 2025 | 2026 | 2025 | ||||||||||||
| Three Months Ended September 30, | Nine Months Ended September 30, | |||||||||||||||
| Basic and diluted net loss per common share: | 2026 | 2025 | 2026 | 2025 | ||||||||||||
| Numerator: | ||||||||||||||||
| Net loss | $ | ( | ) | $ | ( | ) | $ | ( | ) | $ | ( | ) | ||||
| Denominator: | ||||||||||||||||
| Weighted average common shares outstanding | ||||||||||||||||
| Net loss per share of common stock—basic and diluted | $ | ( | ) | $ | ( | ) | $ | ( | ) | $ | ( | ) | ||||
| 13 |
| Table of Contents |
HEPION PHARMACEUTICALS, INC. AND SUBSIDIARIES
Notes to Condensed Consolidated Financial Statements
(Unaudited)
The following outstanding securities at September 30, 2026 and 2025 have been excluded from the computation of basic and diluted weighted shares outstanding, as they would have been anti-dilutive due to net loss:
Schedule of Outstanding Securities Excluded from Computation of Basic and Diluted Weighted Shares Outstanding
| 2026 | 2025 | |||||||
| Nine Months Ended September 30, | ||||||||
| 2026 | 2025 | |||||||
| Common shares issuable for: | ||||||||
| Series A preferred stock | ||||||||
| Series C preferred stock | ||||||||
| Stock options | ||||||||
| Warrants – liability classified | ||||||||
| Warrants – equity classified | ||||||||
Convertible note (convertible upon stockholder approval) | — | |||||||
| Total | ||||||||
10. Commitments and Contingencies
Legal Proceedings
We are involved in various legal proceedings. Significant judgment is required to determine both the likelihood and the estimated amount of a loss related to such matters. Additionally, while any litigation contains an element of uncertainty, we have at this time no reason to believe that the outcome of such proceedings or claims will have a material adverse effect on our consolidated financial condition or results of operations.
| 14 |
| Table of Contents |
HEPION PHARMACEUTICALS, INC. AND SUBSIDIARIES
Notes to Condensed Consolidated Financial Statements
(Unaudited)
Employment Agreements
On May 5, 2026, we entered into an employment agreement with each of Vincent LoPriore, our Executive Chairman (the “LoPriore Employment Agreement”) and Gary Stetz, our former Chief Executive Officer and current Chief Financial Officer (the “Stetz Employment Agreement”). In addition, on August 1, 2026, we entered into an employment agreement with Sireesh Appajosyula, our former Chief Operating Officer and current Chief Executive Officer (the “Appajosyula Employment Agreement”).
The
LoPriore Employment Agreement shall continue for a period of five years and, thereafter, shall automatically renew for successive one-year
terms unless either party provides the other party with written notice of non-renewal at least 60 days prior to the last day of the then
current term. Pursuant to the LoPriore Employment Agreement, Mr. LoPriore shall:
In the event Mr. LoPriore’s employment is terminated by the Company other than as a result of his death or Disability and other than for Cause, or if Mr. LoPriore terminates his employment for Good Reason (as defined in the LoPriore Employment Agreement), then, in addition to accrued compensation, the Company shall (i) continue to pay Mr. LoPriore’s base salary and provide health benefits for a period of 12 months following the termination date or, in the case of benefits, such time as Mr. LoPriore receives equivalent coverage and benefits under plans and programs of a subsequent employer; and (ii) provide such other or additional benefits, if any, as may be provided under applicable employee benefit plans, programs and/or arrangements of the Company (other than any severance plans or programs). In addition, all unvested time-based equity awards (including Restricted Shares and Stock Options) shall be immediately and fully accelerated and become vested. Moreover, Stock Options that have vested as of the termination date shall remain exercisable until the earlier of (i) 60 months following such termination and (ii) the expiration date of the Stock Option.
The
Stetz Employment Agreement shall continue for a period of five years and, thereafter, shall automatically renew for successive one year
terms unless either party provides the other party with written notice of non-renewal at least 60 days prior to the last day of the then
current term. Pursuant to the Stetz Employment Agreement, Mr. Stetz shall:
In the event Mr. Stetz’s employment is terminated by the Company other than as a result of his death or Disability and other than for Cause, or if Mr. Stetz terminates his employment for Good Reason (as defined in the Stetz Employment Agreement), then, in addition to accrued compensation, the Company shall (i) continue to pay Mr. Stetz’s base salary and provide health benefits for a period of 12 months following the termination date or, in the case of benefits, such time as Mr. Stetz receives equivalent coverage and benefits under plans and programs of a subsequent employer; and (ii) provide such other or additional benefits, if any, as may be provided under applicable employee benefit plans, programs and/or arrangements of the Company (other than any severance plans or programs). In addition, all unvested time-based equity awards (including Restricted Shares and Stock Options) shall be immediately and fully accelerate and become vested. Moreover, Stock Options that have vested as of the termination date shall remain exercisable until the earlier of (i) 60 months following such termination and (ii) the expiration date of the Stock Option.
The
Appajosyula Employment Agreement shall continue for a period of five years and, thereafter, shall automatically renew for successive
one year terms unless either party provides the other party with written notice of non-renewal at least 60 days prior to the last day
of the then current term. Pursuant to the Appajosyula Employment Agreement, Dr. Appajosyula shall: (i) receive a base salary of $
In the event Dr. Appajosyula’s employment is terminated by the Company other than as a result of his death or Disability and other than for Cause, or if Dr. Appajosyula terminates his employment for Good Reason (as defined in the Appajosyula Employment Agreement), then, in addition to accrued compensation, the Company shall (i) continue to pay Dr. Appajosyula’s base salary and provide health benefits for a period of 12 months following the termination date or, in the case of benefits, such time as Dr. Appajosyula receives equivalent coverage and benefits under plans and programs of a subsequent employer; and (ii) provide such other or additional benefits, if any, as may be provided under applicable employee benefit plans, programs and/or arrangements of the Company (other than any severance plans or programs). In addition, all unvested time-based equity awards (including Restricted Shares and Stock Options) shall be immediately and fully accelerate and become vested. Moreover, Stock Options that have vested as of the termination date shall remain exercisable until the earlier of (i) 60 months following such termination and (ii) the expiration date of the Stock Option.
On March 16, 2026, Dr. Kaouthar Lbiati, the Chief Executive Officer of Hepion Pharmaceuticals, Inc. (the “Company”) informed the Board of Directors (the “Board”) of the Company that she was resigning as Chief Executive Officer for personal reasons, effective immediately.
On
April 13, 2026 (the “Separation Date”), the Company entered into a separation agreement with Dr. Lbiati pursuant to which,
among other things, she was paid (i) $
Further, pursuant to the separation agreement, Dr. Lbiati agreed to a general release and confidentiality. Also on April 13, 2026, Dr. Lbiati resigned as a director of the Company.
Operating Lease
On
September 3, 2026, the Company entered into a lease agreement (the “Red Bank Lease”) with West Street Ventures LLC (the “Landlord”)
for office space. The Landlord is owned by the Company’s Executive Chairman (see Note 11 – Related
Party). The lease expires on August 31, 2029 and base rent is $
The
lease is classified as an operating lease and the Company recognized a right-of-use asset of $
As of September 30, 2026, future minimum payments under the Red Bank lease were:
Schedule of Future Minimum Payments
| Year ending December 31, | Amount | |||
| 2026 | $ | |||
| 2027 | ||||
| 2028 | ||||
| 2029 | ||||
| Total undiscounted lease payments | ||||
| Less: imputed interest | ( | ) | ||
| Present value of operating lease liability | $ | |||
| 15 |
| Table of Contents |
HEPION PHARMACEUTICALS, INC. AND SUBSIDIARIES
Notes to Condensed Consolidated Financial Statements
(Unaudited)
11. Related Party
The Company’s related party transactions are described below.
Vincent LoPriore, the Company’s Executive Chairman and a director, is the principal of Gravitas Capital LP (“Gravitas Capital”), a stockholder of the Company. Mr. LoPriore also controls President Street Global LLC (“PSG”) and West Street Ventures LLC (“West Street”), the entity from which the Company leases its office space. During the periods presented, Mr. LoPriore and certain other officers and directors of the Company also served as officers or directors of, and held ownership interests in, Gravitas Life Sciences, LLC (“GLS”) through its sole member, Gravitas Collective Corporation (“Gravitas Collective”). The Company acquired GLS from Gravitas Collective on October 6, 2026 (see Note 12).
Convertible Note and Warrant
As
described in Note 5, on September 3, 2026, the Company issued the $
Loan to GLS
On
September 8, 2026, in connection with the then-proposed acquisition of GLS, the Company loaned $
Officers Shared with GLS
During
the three and nine months ended September 30, 2026, Mr. LoPriore; Sireesh Appajosyula, the Company’s Chief Operating Officer since
August 1, 2026; Chase LoPriore, the Company’s Vice President, Corporate Strategy since July 20, 2026 and a family member of Mr.
LoPriore; and Bobbi Fox-Caminiti, Director of Operations, were also employed by GLS, and Gary Stetz, the Company’s Chief Executive
Officer, was a director of GLS. Each of Mr. LoPriore, Dr. Appajosyula, Mr. C. LoPriore and Ms. Fox-Caminiti devoted approximately 50%
of his or her working time to the Company and was compensated separately by the Company and by GLS under their respective employment
agreements, each of which permits the executive to serve other companies. The condensed consolidated financial statements include only
compensation paid or payable by the Company, which totaled $
Financial Advisory Services
The
Company engaged PSG as its exclusive financial advisor in connection with the acquisition of GLS. The engagement was approved on
behalf of the Company by disinterested directors of the Board. Upon the closing of the acquisition, the Company paid PSG a success
fee of $
Office Lease
The
Company leases office space under the Red Bank Lease from West Street, an entity owned by related parties Sireesh Appajosyula, Chase
LoPriore, Vincent LoPriore, and Gary Stetz II, that commenced on September 3, 2026 at a monthly rent of $
12. Subsequent Events
On October 1, 2026, the Company filed a Certificate of Amendment to its Certificate of Incorporation increasing its
authorized common stock from
On
October 6, 2026, the Company entered into a Membership Interest Purchase Agreement (the “Purchase Agreement”) with Gravitas Life Sciences,
LLC, a Delaware limited liability company (“GLS”), and Gravitas Collective Corp, a Delaware corporation and the sole member
of GLS, pursuant to which the Company agreed to acquire all of the issued and outstanding membership interests (the “Purchase Securities”)
of GLS (the “GLS Transaction”). Pursuant to the Purchase Agreement, Gravitas Collective Corp. sold the Purchase Securities
to the Company in exchange for the right to receive (i) $
In
connection with the GLS Transaction, Gravitas Collective Corp. and Canton Strategic Holdings, Inc. (“Canton”) entered into
a partial payoff confirmation and note assignment dated October 6, 2026 (the “Payoff Letter”), relating to an unsecured promissory
note dated July 17, 2026 between GLS and Canton (the “Canton Note”). Pursuant to the Payoff Letter, the Company paid Canton
$
Vincent LoPriore, Gary Stetz, Sireesh Appajosyula, and Chase LoPriore, each a current director of the Company, are officers of GLS and shareholders of Gravitas Collective Corp. Accordingly, the GLS Transaction constitutes a related party transaction. In light of their respective affiliations with GLS and Gravitas Collective Corp., each of Mr. V. LoPriore, Mr. Stetz, Dr. Appajosyula, and Mr. C. LoPriore recused himself from deliberation and voting on the matter.
On October 9, 2026, the Board appointed Dr. Appajosyula as Chief Executive Officer and Mr. Stetz as Chief Financial Officer.
| 16 |
| Table of Contents |
ITEM 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS
The following discussion should be read in conjunction with our condensed consolidated financial statements and other financial information appearing elsewhere in this quarterly report. In addition to historical information, the following discussion and other parts of this quarterly report contain forward-looking statements. You can identify these statements by forward-looking words such as “plan,” “may,” “will,” “expect,” “intend,” “anticipate,” believe,” “estimate” and “continue” or similar words. Forward-looking statements include information concerning possible or assumed future business success or financial results. You should read statements that contain these words carefully because they discuss future expectations and plans, which contain projections of future results of operations or financial condition or state other forward-looking information. We believe that it is important to communicate future expectations to investors. However, there may be events in the future that we are not able to accurately predict or control. Accordingly, we do not undertake any obligation to update any forward-looking statements for any reason, even if new information becomes available or other events occur in the future.
The forward-looking statements included herein are based on current expectations that involve a number of risks and uncertainties set forth under “Risk Factors” in our Annual Report on Form 10-K as of and for the year ended December 31, 2025 filed with the United States Securities and Exchange Commission (“SEC”) on March 12, 2026, as well as under “Risk Factors” within this Form 10-Q. Accordingly, to the extent that this Report contains forward-looking statements regarding the financial condition, operating results, business prospects or any other aspect of us, please be advised that our actual financial condition, operating results and business performance may differ materially from that projected or estimated by us in forward-looking statements, and you should not unduly rely on such statements.
Overview
Hepion Pharmaceuticals, Inc. (we, our, or us) is a medical diagnostic company headquartered in Red Bank, New Jersey, that was previously focused on the development of drug therapy for treatment of chronic liver diseases. Our cyclophilin inhibitor, rencofilstat (formerly CRV431), was being developed to offer benefits to address multiple complex pathologies related to the progression of liver disease.
On February 25, 2026, we entered into an intellectual property license agreement with Cirna Diagnostics, LLC (“Cirna”) pursuant to which we licensed certain liver disease diagnostic assets from Cirna. We paid an upfront payment of $70,000 during the nine months ended September 30, 2026 and could pay up to $2,350,000 in milestone payments, up to $4,500,000 in sales milestone payments and a royalty payment on net sales in the low single digits. We accounted for this transaction as an asset acquisition. The total upfront consideration of $70,000 was allocated to purchased in-process research and development, and was expensed upon the completion of the transaction. We did not recognize any contingent consideration (milestone payments) given the low probability of meeting those targets. Royalties will be recognized when earned.
During 2026, we entered into employment agreements with each of Vincent LoPriore, our Executive Chairman, Gary Stetz, our former Interim Chief Executive Officer, appointed as Chief Financial Officer in October 2026, and Sireesh Appajosyula, our former Chief Operating Officer, appointed as Chief Executive Officer in October 2026.
Recent Developments
On October 1, 2026, we filed a Certificate of Amendment to our Certificate of Incorporation increasing our authorized common stock from 120,000,000 shares to 750,000,000 shares.
On October 6, 2026, we entered into a Membership Interest Purchase Agreement (the “Purchase Agreement”) with Gravitas Life Sciences, LLC, a Delaware limited liability company (“GLS”), and Gravitas Collective Corp, a Delaware corporation and the sole member of GLS, pursuant to which the Company agreed to acquire all of the issued and outstanding membership interests (the “Purchase Securities”) of GLS (the “GLS Transaction”). Pursuant to the Purchase Agreement, Gravitas Collective Corp. sold the Purchase Securities to the Company in exchange for the right to receive (i) $2,000,000 in cash and (ii) 25,000,000 shares of the Company’s common stock (the “Stock Consideration”), par value $0.0001 per share. The Purchase Agreement contained a cap providing that in no event will the aggregate number of shares of common stock exceed 19.99% of the Company’s outstanding shares of common stock immediately following issuance, with any resulting reduction in shares to be settled in an equitable cash payment. The Company paid an additional $135,000 to Gravitas Collective Corp. The shares of common stock comprising the Stock Consideration are subject to a lock-up restricting transfer until the earlier of (i) the six-month anniversary of the closing date on October 6, 2026 and (ii) the date the shares are registered for resale under an effective registration statement.
GLS is a clinical-stage biotechnology company developing therapeutic candidates in immunology and inflammation. On November 3, 2023, GLS entered into a patent license agreement (the “Avior License Agreement”) with Avior Inc. d/b/a Avior Bio, LLC (“Avior”). The agreement grants GLS an exclusive, sublicensable, worldwide right and license to Licensed Patent Rights and Licensed Technology to develop, make, use, sell, import, export and commercialize GV104 (formerly TH104), and to practice the Licensed Technology in connection with the foregoing, each as defined in that agreement. In February 2023 the U.S. Food and Drug Administration (“FDA”) approved an investigational new drug (“IND”) application for GV104, a transmucosal buccal film of nalmefene. Nalmefene is an opioid antagonist first approved in the United States in 1995 and is marketed in injectable and limited nasal presentations. The film adheres to the buccal mucosa, and the drug is absorbed across the mucosa potentially without first-pass hepatic metabolism.
In April 2024 GLS submitted a pre-investigational new drug meeting request to the FDA for the proposed indication of temporary prophylaxis of respiratory and/or central nervous system depression in military personnel and chemical incident responders entering an area contaminated with high-potency opioids (“PrHPO”). The approval pathway GLS proposed is a 505(b)(2) New Drug Application (“NDA”) for GV104 relying on the FDA’s prior findings for Revex® (nalmefene hydrochloride injection). The FDA responded in March 2025 stating that “additional clinical studies do not appear to be necessary to define the prophylactic dosing window at this time.” GLS deprioritized a previous clinical program for pruritus in primary biliary cholangitis and intends to continue to rely on the existing active IND for PrHPO development.
The clinical bridging study for the 505(b)(2) application compared a 16 mg GV104 buccal film against 1 mg intravenous nalmefene in a randomized two-way crossover in 20 healthy subjects, reporting an absolute bioavailability of 45.9 percent, a median Tmax of 2.0 hours and a mean half-life of 14 hours. The FDA identified extractables and leachables studies and elemental impurities as required, and further nonclinical studies as possibly needed to qualify new excipients and impurities, as part of the Chemistry, Manufacturing and Controls (“CMC”) package required for an NDA. The FDA confirmed that nonclinical and chemistry data on file under the existing IND may be cross-referenced to the PrHPO application. In August 2025 GLS submitted a Type D briefing package containing a pharmacokinetic-pharmacodynamic modeling plan in place of further clinical work. In October 2025 the FDA endorsed the model and requested a validated worst-case fentanyl challenge dose. In July 2026 GLS submitted the completed cardiac-arrest simulation.
On October 26, 2026, we announced that the FDA had provided written responses to the July 2026 briefing package, re-affirming the overall modeling approach and providing comments on the model structure, the presentation of results and the fentanyl challenge simulations, which the FDA stated would improve the Company’s ability to demonstrate long-term prophylactic protection. In the simulation as submitted, a single 16 mg GV104 buccal film taken at least 15 minutes before exposure prevented every simulated fentanyl-induced cardiac arrest in 200 virtual subjects at lethal fentanyl doses, with protection predicted at a median of 10 to 15 minutes after dosing. GLS believes each comment is addressable within its existing modeling program and intends to submit its response promptly; the revised analysis may produce different results.
GLS is also developing GV104 for the treatment of gambling disorder, a psychiatric condition with no FDA-approved pharmacotherapy. On October 19, 2026, we announced that the FDA’s Division of Psychiatry had issued written responses to GLS’s Type B pre-IND meeting request for GV104 in gambling disorder, addressing the 505(b)(2) regulatory pathway, the nonclinical package and the design of a planned Phase 2 study. The FDA confirmed that GLS may cross-reference the nonclinical and CMC sections of the existing IND, stated that the nonclinical studies on file appear potentially sufficient to support 12-week clinical dosing in a Phase 2 study, and stated that the planned Phase 2 proof-of-concept design and proposed primary endpoint are, in general, appropriate. GLS intends to file an IND for GV104 in gambling disorder in 2027; the final Phase 2 design remains subject to change following IND review. FDA feedback at the pre-IND stage is advisory and not binding on the Agency.
| 17 |
| Table of Contents |
GLS intends to file an NDA for PrHPO after conducting CMC work covering the manufacturing process, quality control and product stability for the buccal film. No clinical study is in progress or scheduled for the dosing window and the extractables and leachables studies the FDA identified require commercial-scale registration batches, which GLS intends to begin producing in 2027.
On September 11, 2024, GLS entered into a Patent License Agreement (the “Intract Agreement”) with Intract Pharma Limited (“Intract”). Under that agreement GLS exclusively licensed GV023 (formerly INT-023/TH023), an oral formulation of infliximab, an anti-tumor necrosis factor-alpha (“TNF-α”) monoclonal antibody. Infliximab is a purified, recombinant DNA-derived chimeric IgG monoclonal antibody containing murine and human components that inhibits TNF-α. The agreement grants global development and commercialization rights outside South Korea to Intract’s Soteria® and Phloral® delivery platforms and includes an existing supply agreement for infliximab. Phloral® is an enteric coating that releases on a pH signal and on a microbiota-enzymatic signal. Soteria® protects the antibody through gastric transit and limits proteolytic degradation. GV023 contains no device component and is currently in preclinical development. A minipig study reported proximal colon tissue exposure with minimal systemic exposure and the MHRA has provided written scientific advice, applicable in the United Kingdom, that no further preclinical studies are required and has accepted the existing infliximab safety data. Initiation of a first-in-human study in Australia or the European Union requires the corresponding national process, on which GLS intends to obtain further guidance in 2027 planning CMC and first-in-man programs.
FINANCIAL OPERATIONS OVERVIEW
From inception through September 30, 2026, we have an accumulated deficit of $252.7 million, and we have not generated any revenue from operations.
CRITICAL ACCOUNTING ESTIMATES
Our condensed consolidated financial statements are prepared in accordance with accounting principles generally accepted in the United States (U.S. GAAP). The preparation of these condensed consolidated financial statements requires us to make estimates and assumptions that affect the reported amounts of assets, liabilities, costs and expenses, income taxes and related disclosures. On an ongoing basis, we evaluate our estimates and assumptions. Our actual results may differ from these estimates under different assumptions or conditions.
During the nine months ended September 30, 2026, there were no significant changes to our critical accounting estimates from those described in the “Management’s Discussion and Analysis of Financial Condition and Results of Operations” contained in the Annual Report on Form 10-K for the year ended December 31, 2025.
RECENT ACCOUNTING PRONOUNCEMENTS
Please refer to Note 3 of Notes to Condensed Consolidated Financial Statements, Recent Accounting Pronouncements, in this Quarterly Report on Form 10-Q.
RESULTS OF OPERATIONS
Comparison of the three months ended September 30, 2026 and 2025:
| Three Months Ended September 30, | ||||||||||||
| 2026 | 2025 | Change | ||||||||||
| Revenues | $ | — | $ | — | $ | — | ||||||
| Costs and Expenses: | ||||||||||||
| Research and development | 134,654 | — | 134,654 | |||||||||
| General and administrative | 1,415,892 | 527,902 | 887,990 | |||||||||
| Asset impairment loss | — | — | — | |||||||||
| Total operating expenses | 1,550,546 | 527,902 | 1,022,644 | |||||||||
| Loss from operations | (1,550,546 | ) | (527,902 | ) | (1,022,644 | ) | ||||||
| Other income (expense): | ||||||||||||
| Interest income (expense) | (3,494 | ) | 8,116 | (11,610 | ) | |||||||
| Other income (expense), net | 6,255 | — | 6,255 | |||||||||
| Change in fair value of derivative financial instruments—warrants | (3,035,135 | ) | 47,280 | (3,082,415 | ) | |||||||
| Net loss | $ | (4,582,920 | ) | $ | (472,506 | ) | $ | (4,110,414 | ) | |||
We had no revenues during the three months ended September 30, 2026 and 2025, because we have not commercialized any of our products and we do not expect to have such products for several years, if at all.
Research and development expenses for the three months ended September 30, 2026 and 2025 was approximately $0.1 million and $0, respectively. The increase in research and development expense in 2026 is primarily related to an increase in research and development personnel during 2026.
General and administrative expenses for the three months ended September 30, 2026 and 2025 was approximately $1.4 million and $0.5 million, respectively. The increase of $0.9 million was primarily due to approximately $0.5 million increase in personnel costs of our general and administrative employees, $0.1 million in professional fees, $0.2 million in non-cash stock-based compensation for our general and administrative personnel and $0.1 million increase in public company costs.
Other income (expense), net for the three months ended September 30, 2026 consists of a gain of $21,799 from the return of 346,020 shares of Common Stock pursuant to the New Day Termination Agreement, offset by $15,544 of offering costs allocated to the liability-classified warrants issued in the July 2026 Offering. The change in fair value of derivative financial instruments – warrants of approximately $3.0 million for the three months ended September 30, 2026 is non-cash. It reflects the increase in the fair value of outstanding warrants, including the July 2026 and August 2026 Offering warrants classified as liabilities, primarily driven by the increase in our stock price.
| 18 |
| Table of Contents |
Comparison of the nine months ended September 30, 2026 and 2025:
| Nine Months Ended September 30, | ||||||||||||
| 2026 | 2025 | Change | ||||||||||
| Revenues | $ | — | $ | — | $ | — | ||||||
| Costs and Expenses: | ||||||||||||
| Research and development | 255,572 | 445,512 | (189,940 | ) | ||||||||
| General and administrative | 3,304,974 | 2,705,750 | 599,224 | |||||||||
| Asset impairment loss | — | 402,746 | (402,746 | ) | ||||||||
| Total operating expenses | 3,560,546 | 3,554,008 | 6,538 | |||||||||
| Loss from operations | (3,560,546 | ) | (3,554,008 | ) | (6,538 | ) | ||||||
| Other income (expense): | ||||||||||||
| Interest income (expense) | 620 | (11,829 | ) | 26,222 | ||||||||
| Other income (expense), net | 6,255 | — | 6,255 | |||||||||
| Change in fair value of derivative financial instruments—warrants | (3,088,277 | ) | (4,055,128 | ) | 966,851 | |||||||
| Net loss | $ | (6,641,948 | ) | $ | (7,620,965 | ) | $ | 979,017 | ||||
We had no revenues during the nine months ended September 30, 2026 and 2025, because we have not commercialized any of our products and we do not expect to have such products for several years, if at all.
Research and development expenses for the nine months ended September 30, 2026 and 2025 were approximately $0.3 million and $0.4 million, respectively. The decrease in research and development expense in 2026 is primarily related to the purchase of in-process research and development related to the New Day asset acquisition in 2025, partially offset by Cirna license fees incurred in 2026 and an increase in research and development personnel.
General and administrative expenses for the nine months ended September 30, 2026 and 2025 were approximately $3.3 million and $2.7 million, respectively. The increase of approximately $0.6 million was primarily due to an increase of $1.1 million in personnel costs of our general and administrative personnel and $0.2 million in non-cash stock-based compensation for our general and administrative personnel. These increases were partially offset by a $0.6 million decrease in legal and accounting fees and $0.1 million decrease in public company costs.
Asset impairment loss for the nine months ended September 30, 2026 and 2025 was $0 and $0.4 million, respectively. The decrease in asset impairment loss is related to the asset from the New Day license agreement that was fully impaired in prior year.
The change in fair value of derivative financial instruments – warrants for the nine months ended September 30, 2026 of approximately $3.1 million is non-cash and reflects the increase in the fair value of outstanding warrants, including the July 2026 and August 2026 Offering warrants classified as liabilities, primarily driven by the increase in our stock price. For the nine months ended September 30, 2025, the change in fair value of $4.1 million related to the 2025 Series A and Series B warrants. Other income (expense), net for the nine months ended September 30, 2026 consists of the $21,799 gain on the return of common stock, offset by $15,544 of offering costs allocated to the liability-classified warrants.
| 19 |
| Table of Contents |
Liquidity and Capital Resources
Sources of Liquidity
We have funded our operations through September 30, 2026 primarily through the issuance of convertible preferred stock, warrants, the issuance and sale of shares of our common stock, and subsequent issuances of shares of our common stock through at-the market offerings.
On April 21, 2026, we entered into securities purchase agreements with certain accredited investors pursuant to which the Company agreed to sell and issue an aggregate of 17,500,000 shares of Common Stock in a private placement offering at an offering price of $0.04 per share for gross proceeds of $700,000. The Offering closed on April 21, 2026.
On July 31, 2026, we entered into securities purchase agreements with certain accredited investors pursuant to which the Company agreed to sell and issue an aggregate of 61,100,000 shares of Common Stock and warrants to purchase 61,100,000 shares of Common Stock, in a private placement offering at an offering price of $0.05 per share for gross proceeds of approximately $3.1 million. The warrants are exercisable at an exercise price of $0.06 per share for five years from the date of issuance. The July 2026 Offering closed on August 3, 2026. In addition, during the third quarter of 2026, we sold an aggregate of 10,200,000 shares of Common Stock and warrants to purchase 10,200,000 shares of Common Stock in the August 2026 Offering and the September 2026 Offering at an offering price of $0.05 per share for aggregate gross proceeds of approximately $0.5 million.
Future Funding Requirements
We have no products approved for commercial sale in the United States. To date, we have devoted substantially all of our resources to organizing and staffing our company, business planning, raising capital, undertaking preclinical studies and clinical trials of our former product candidates. As a result, we are not profitable and have incurred losses in each period since our inception in 2013. As of September 30, 2026, we had an accumulated deficit of $252.7 million. We expect to continue to incur significant losses for the foreseeable future.
We may encounter unforeseen expenses, difficulties, complications, delays and other unknown factors that may adversely affect our business. The size of our future net losses will depend, in part, on the rate of future growth of our expenses and our ability to generate revenue. Our prior losses and expected future losses have had and will continue to have an adverse effect on our stockholders’ equity and working capital.
We will require additional financing and a failure to obtain this necessary capital could force us to delay, limit, reduce or terminate our operations.
Since our inception, we have invested a significant portion of our efforts and financial resources in research and development activities for our non-replicating and replicating technologies and our product candidates derived from these technologies. We believe that we will continue to expend substantial resources for the foreseeable future in connection with the development of acquired assets in connection with our strategic alternatives strategy. In addition, other unanticipated costs may arise.
| 20 |
| Table of Contents |
Our future capital requirements depend on many factors, including:
| ● | the scope, progress, results and costs of researching and developing our current and future product candidate and programs, and of conducting preclinical studies and clinical trials; | |
| ● | the number and development requirements of other product candidates that we may pursue, and other indications for our current product candidate that we may pursue; | |
| ● | the timing of, and the costs involved in, obtaining regulatory and marketing approvals and developing our ability to establish sales and marketing capabilities, if any, for our future product candidates we develop if clinical trials are successful; | |
| ● | our ability to establish and maintain collaborations, strategic licensing or other arrangements and the financial terms of such agreements; | |
| ● | the cost of commercialization activities for our future product candidates that we may develop, whether alone or with a collaborator; | |
| ● | the costs involved in preparing, filing, prosecuting, maintaining, expanding, defending and enforcing patent claims, including litigation costs and the outcome of such litigation; | |
| ● | the timing, receipt and amount of sales of, or royalties on, our future products, if any; and |
A change in the outcome of any of these or other variables with respect to the development of any of our future product candidates could significantly change the costs and timing associated with the development of that product candidate. Furthermore, our operating plans may change in the future, and we will need additional funds to meet operational needs and capital requirements associated with such operating plans.
The condensed consolidated financial statements as of September 30, 2026 have been prepared under the assumption that we will continue as a going concern within one year after the financial statements are issued. Due to our accumulated deficit and our recurring and expected continuing losses from operations, we have concluded there is substantial doubt in our ability to continue as a going concern without additional capital becoming available to attain further operating efficiencies and, ultimately, to generate revenue. Our financial statements do not include any adjustments that might result from the outcome of this uncertainty.
| 21 |
| Table of Contents |
We will be required to raise additional capital to continue to fund operations. We cannot be certain that additional funding will be available on acceptable terms, or at all. To the extent that we raise additional funds by issuing equity securities, our stockholders may experience significant dilution. Any debt financing, if available, may involve restrictive covenants that impact our ability to (i) acquire new product candidates; or (ii) relinquish or otherwise dispose of rights to technologies, product candidates or products that we would otherwise seek to develop or commercialize on unfavorable terms.
Cash Flows
The following table summarizes our cash flows for the following periods:
| Nine Months Ended September 30, | ||||||||
| 2026 | 2025 | |||||||
| Net cash provided by (used in): | ||||||||
| Operating activities | $ | (1,697,270 | ) | $ | (2,938,745 | ) | ||
| Investing activities | (500,000 | ) | (132,117 | ) | ||||
| Financing activities | 4,624,554 | 4,985,532 | ||||||
As of September 30, 2026, we had working capital of $3.8 million compared to working capital of $2.8 million as of December 31, 2025. The increase of $1.0 million in working capital is primarily due to proceeds from equity issuances during the period, partially offset by operating costs incurred during the period.
Operating Activities:
Net cash used in operating activities was $1.7 million for the nine months ended September 30, 2026, consisting primarily of our net loss of $6.6 million, offset by change in prepaid expenses of $1.1 million, non-cash stock-based compensation of $0.2 million, change in accounts payable and accrued expense of $0.6 million, non-cash change in fair value of derivative financial instruments – warrants of $3.1 million and $15,544 of offering costs allocated to warrant liabilities.
Net cash used in operating activities was $2.9 million for the nine months ended September 30, 2025, consisting primarily of our net loss of $7.6 million, adjusted for non-cash charges of $4.5 million, including $4.1 million in change in fair value of derivative warrants and $0.4 million in asset impairment loss. Changes in operating assets and liabilities increased by $0.2 million.
Investing Activities:
Net cash used in investing activities was $0.5 million for the nine months ended September 30, 2026, related to a related party loan receivable. Net cash used in investing activities was $0.1 million for the nine months ended September 30, 2025 related to the acquisition of licenses from New Day Diagnostics.
Financing Activities:
Net cash provided by financing activities was $4.6 million for the nine months ended September 30, 2026, consisting of net proceeds of $4.3 million from equity offerings and $0.5 million of proceeds from a note payable, offset by payment of notes payable of $0.1 million and equity issuance costs of $0.1 million.
Net cash provided by financing activities was $5.0 million for the nine months ended September 30, 2025, due primarily to $9.0 million in net proceeds received from the exercise of the warrants and equity issuance offset by $3.2 million payment on notes payable and equity issuance costs of $0.8 million.
| 22 |
| Table of Contents |
ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK
Not applicable.
ITEM 4. CONTROLS AND PROCEDURES
Evaluation of Disclosure Controls and Procedures
Based on an evaluation of our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) of the Securities Exchange Act of 1934, as amended) required by paragraph (b) of Rule 13a-15 or Rule 15d-15, as of September 30, 2026, our Principal Executive Officer and Principal Financial Officer have concluded that due to the material weaknesses in our internal control over financial reporting noted below, our disclosure controls and procedures were not effective.
| ● | Due to cost-cutting measures, the Company’s control environment was ineffective as they did not maintain a sufficient complement of personnel to execute controls as designed including the absence of proper segregation of duties. Such impacted controls include indirect controls affecting risk assessment, information & communication, and monitoring components of COSO along with certain control activities including both business process controls and information technology general controls. | |
| ● | Lack of proper design and implementation of controls over formal review, approval, and evaluation of non-core, complex accounting transactions. | |
| ● | Lack of proper design and implementation of certain controls over the income tax provision and management’s review of the income tax provision. The Company utilized a third-party to assist in the preparation of the tax provision. Specifically, the Company did not sufficiently design and implement controls related to the completeness and accuracy of certain aspects of the tax provision and the completeness and accuracy of income tax disclosures. |
Remediation of Material Weaknesses
We are committed to the remediation of the material weaknesses described above, as well as the continued improvement of our internal control over financial reporting. During the nine months ended September 30, 2026 and through the date of this report, we implemented the following remedial actions:
| ● | Segregation of duties and review of key workpapers. We reassigned responsibilities among our finance and accounting personnel to improve segregation of duties. Key account reconciliations, journal entries and financial reporting workpapers are now prepared by one individual and reviewed and approved by our Chief Financial Officer, with evidence of review retained. | |
| ● | Accounts payable and cash disbursements. We implemented a multi-level review and approval process for accounts payable and payments. Invoices are approved by the responsible budget owner before payment. Payments are reviewed and approved by more than one individual, and the person who prepares a payment is not the person who approves or releases it. | |
| ● | Complex accounting transactions. We engaged a third-party accounting specialist to assist management in evaluating and documenting the accounting for non-routine and complex transactions, including warrants, convertible debt and business combinations. Technical accounting memoranda are prepared for these transactions and reviewed by our Chief Financial Officer before the related amounts are recorded. | |
| ● | Board oversight. We expanded our Board of Directors to seven members, which strengthens oversight of financial reporting and internal control. |
While these actions represent progress, the material weaknesses will not be considered remediated until the enhanced controls have operated for a sufficient period of time and management has concluded, through testing, that they are designed and operating effectively.
Changes in Internal Control over Financial Reporting
Except as noted above, there have been no changes in our internal controls over financial reporting during the three months ended September 30, 2026 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.
| 23 |
| Table of Contents |
PART II. OTHER INFORMATION
ITEM 1A. RISK FACTORS
There have been no material changes from the risk factors disclosed in our Form 10-K for the year ended December 31, 2025.
ITEM 5. Other Information
During
the three months ended September 30, 2026, no director or officer
ITEM 6. EXHIBITS
| 2.1 | Membership Interest Purchase Agreement, dated as of October 6, 2026 by and among Hepion Pharmaceuticals, Inc., Gravitas Life Sciences, LLC and Gravitas Collective Corp. (incorporated by reference to Exhibit 2.1 to Form 8-K filed on October 9, 2026) | |
| 3.1 | Certificate of Amendment to Certificate of Incorporation of Hepion Pharmaceuticals, Inc. (incorporated by reference to Exhibit 3.1 to Form 8-K filed on October 2, 2026) | |
| 4.1 | Form of Convertible Note (incorporated by reference to Exhibit 4.1 to Form 8-K filed on September 8, 2026). | |
| 4.2 | Form of Warrant (incorporated by reference to Exhibit 4.2 to Form 8-K filed on September 8, 2026) | |
| 10.1 | Form of Convertible Note Purchase Agreement (incorporated by reference to Exhibit 10.1 to Form 8-K filed on September 8, 2026) | |
| 10.2 | Form of Convertible Note Security Agreement (incorporated by reference to Exhibit 10.2 to Form 8-K filed on September 8, 2026). | |
| 10.3 | Employment Agreement between Sireesh Appajosyula and Hepion Pharmaceuticals, Inc. dated August 1, 2026 | |
| 31.1 | Certification of Chief Executive Officer required under Rule 13a-14(a)/15d-14(a) under the Exchange Act. | |
| 31.2 | Certification of Chief Financial Officer required under Rule 13a-14(a)/15d-14(a) under the Exchange Act. | |
| 32.1 | Certification of Chief Executive Officer pursuant to 18 U.S.C Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002. | |
| 32.2 | Certification of Chief Financial Officer pursuant to 18 U.S.C Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002. | |
| 101.INS | Inline XBRL Instance Document-the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document. | |
| 101.SCH | Inline XBRL Taxonomy Extension Schema | |
| 101.CAL | Inline XBRL Taxonomy Extension Calculation Linkbase | |
| 101.DEF | Inline XBRL Taxonomy Extension Definition Linkbase | |
| 101.LAB | Inline XBRL Taxonomy Label Linkbase | |
| 101.PRE | Inline XBRL Taxonomy Extension Presentation Linkbase | |
| 104 | Cover Page Interactive Data File (formatted as Inline XBRL in Exhibit 101) |
| 24 |
| Table of Contents |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| HEPION PHARMACEUTICALS, INC. (Registrant) | ||
| Date: November 13, 2026 | By: | /s/ Sireesh Appajosyula |
| Sireesh Appajosyula | ||
| Chief Executive Officer | ||
| (Principal Executive Officer) | ||
| 25 |